San Diego, California — According to state and local economic development sources Neurocrine Biosciences plans to invest $3,780,560.00 to build out 43,960 square feet of new space in San Diego. The company plans to occupy the new space at 12790 El Camino Real Unit Floors 1&2 in San Diego, on or about August 1, 2021. According to the company website Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, uterine fibroids and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.

To learn more about Neurocrine Biosciences, visit http://www.neurocrine.com/

Company Contact:
Kevin Gorman, Chief Executive Officer
https://www.linkedin.com/in/kevin-gorman-4266076/
858-617-7600

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved